Erasca

ERAS

Market cap $1.02B

3.60 USD

+0.22

6.51%

At close Updated Dec 12, 4:00 PM EST

Pre-market

After hours

3.76

+0.16

4.44%

1 day

6.51%

5 days

10.09%

1 month

35.85%

3 months

130.77%

6 months

135.29%

Year to date

33.33%

1 year

36.88%

5 years

-79.35%

10 years

-79.35%

About: Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Employees: 129

Healthcare Biotechnology